Company Profile

Akouos LLC (AKA: Akouos Inc)
Profile last edited on: 6/12/2024      CAGE: 7NJN1      UEI: Q8ENRG23NEM3

Business Identifier: Restoring and preserving hearing: developing precision therapies for forms of sensorineural hearing loss
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

645 Summer Street Suite 200
Boston, MA 02210
   (857) 410-1818
Location: Single
Congr. District: 08
County: Suffolk

Public Profile

In early December 2022 it was announced that Eli Lilly had completed acquisition of Akouos LLC. With ties to Harvard and Mass Eye and Ear, founded by major players in the fields of neurotology, inner ear drug delivery, clinical genetics, and AAV gene therapy, since startup Akouos has been focused on treating hearing disorders with clear etiology in genetically-defined patient populations. The firm's ability to match precision therapies with the right patients is rooted in their understanding of hearing loss genetics and pathophysiology. To underpin launch of the firm, Akouos entered into strategic license agreements with Lonza and with Massachusetts Eye and Ear for exclusive rights to the Anc-AAV gene therapy platform for all hearing and balance disorders. The firm's name - ????? in Greek - translates to "Listen" in English

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2017 1 NIH $223,568
Project Title: Minimally Invasive Delivery System for Treatment of Inner Ear Disorders

Key People / Management

  Emmanuel John (Manny) Simons -- CEO, President and Co-Founder

  Michael J McKenna -- Chief Medical Officer

  William F Sewell

  Richard J Smith D

  Luk H Vandenberghe

  Jennifer Wellman -- Senior Vice President, Regulator